Disease · MONDO_0012727
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm 1 -Etanercept vs ARM 2 Placebo: Determine if Etanercept Treatment Alters the Rate of Coronary Artery Dilation and Disease (CAD) at 2 and 6 Weeks After Treatment in Patients With Dilated Coro | 56 of 100 | 53 of 101 | 201 | NCT00841789 | Trial comparisons |
| Arm 1 -Etanercept vs ARM 2 Placebo: IVIG Refractory | 13 of 100 | 22 of 101 | 201 | NCT00841789 | Trial comparisons |
| Arm 1 -Etanercept vs Arm -2 Placebo: deaths from any cause | 0 of 99 | 0 of 102 | 201 | NCT00841789 | Trial comparisons |
| Arm 1 -Etanercept vs Arm -2 Placebo: serious adverse events | 9 of 99 | 10 of 102 | 201 | NCT00841789 | Trial comparisons |
| Infliximab Arm vs Placebo Arm: serious adverse events | 22 of 98 | 17 of 98 | 196 | NCT00760435 | Trial comparisons |
| Infliximab vs Placebo: The Number of Subjects in Each Arm That Have Persistent or Recrudescent Fever 24 Hours After Completion of the Intravenous Immunoglobulin (IVIG) Infusion | 11 of 98 | 11 of 97 | 195 | NCT00760435 | Trial comparisons |
| IVIG vs Infliximab: Number of Participants With IVIG and Infliximab Infusion Reactions and Complications | 1 of 49 | 2 of 54 | 103 | NCT03065244 | Trial comparisons |
| IVIG vs Infliximab: deaths from any cause | 0 of 49 | 0 of 54 | 103 | NCT03065244 | Trial comparisons |
| IVIG vs Infliximab: serious adverse events | 27 of 49 | 10 of 54 | 103 | NCT03065244 | Trial comparisons |
| IVIG vs Infliximab: Number of Participants With Cessation of Fever Within 24h of Initiation of Study Treatment With no Fever Recurrence Within Next 7 Days. | 25 of 49 | 40 of 52 | 101 | NCT03065244 | Trial comparisons |
| TA-650 vs Polyethylene Glycol-treated Human Immunoglobulin (VGIH): serious adverse events | 0 of 16 | 1 of 15 | 31 | NCT01596335 | Trial comparisons |
| IVIG Arm (2 gr/kg) vs Infliximab (5mg/kg): serious adverse events | 2 of 12 | 3 of 12 | 24 | NCT00271570 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0012727/comparisons